Source-grounded facts extracted from Absci Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Absci Corp shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“The Company’s stockholders ratified the selection of Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026 in Proposal II, with the votes cast as follows: For Against Abstain 111,058,992 2,198,390 97,655”
Absci Corp shareholders approved Election of two Class II directors: Prof Sir Menelas Pangalos, Ph.D. and Daniel Rabinovitsj at the 2026-06-04 meeting.
“The Company’s stockholders voted for the Class II directors as follows: Class II Director Nominees For Withhold Broker Non-Votes Prof Sir Menelas Pangalos, Ph.D. 74,118,258 9,332,380 29,904,399 Daniel Rabinovitsj 69,590,534 13,860,104 29,904,399”
Absci Corp reported first quarter ended March 31, 2026 results: revenue $0.2 million.
“Revenue was $0.2 million for the three months ended March 31, 2026, compared to $1.2 million for the three months ended March 31, 2025.”
Absci Corp reported the quarter and full year ended December 31, 2025 results: revenue $0.7 million for the three months ended December 31, 2025 compared to $0.7 million for the three months ended December 3.
“On March 24, 2026, Absci Corporation (the “Company”) announced its financial results for the fourth quarter ended December 31, 2025.”
Amrit Nagpal resigned as Director at Absci Corp.
“On April 25, 2025, Amrit Nagpal notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of April 25, 2025.”
Absci Corp reported the quarter ended March 31, 2024 results: revenue $0.9 million, net income $22.0 million.
“Revenue was $0.9 million for the three months ended March 31, 2024 compared to $1.3 million for the three months ended March 31, 2023.”
Absci Corp reported financial results for the fourth quarter and full year ended December 31, 2023.
“On March 21, 2024, Absci Corporation (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2023.”
Absci Corp entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Cowen & Company, LLC valued at public offering price of $4.50 per share (effective 2024-02-27).
“On February 27, 2024, Absci Corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Morgan Stanley & Co. LLC and Cowen & Company, LLC (the “ Underwriters ”), relating to the issuance and sale of an aggregate of 16,700,000 shares (the “ Underwritten Shares ”) of the Company’s common stock”
Professor Sir Menelas Pangalos was appointed as Director at Absci Corp.
“On December 5, 2023, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Professor Sir Menelas Pangalos to the Board effective January 1, 2024.”
Absci Corp reported the quarter ended September 30, 2023 results: revenue $0.7 million, net income Net loss was $22.0 million.
“Revenue was $0.7 million for the three months ended September 30, 2023”
Sarah Korman departed as Chief Legal Officer and interim Chief Business Officer at Absci Corp.
“On August 16, 2023, Absci Corporation (the “Company”) and Sarah Korman, Ph.D., JD mutually agreed that Dr. Korman’s employment with the Company will end effective as of September 15, 2023”
Absci Corp reported second quarter ended June 30, 2023 results: revenue $3.4 million, net income Net loss was $41.7 million. Guidance reaffirmed.
“Revenue was $3.4 million for the three months ended June 30, 2023 compared to $1.0 million for the three months ended June 30, 2022.”
Zachariah Jonasson was appointed as Chief Financial Officer and Chief Business Officer at Absci Corp.
“On August 11, 2023, the Company’s Board of Directors appointed Zachariah Jonasson, Ph.D. as the Company’s Chief Financial Officer, Chief Business Officer and Treasurer, effective as of August 31, 2023.”
Gregory Schiffman retired as Chief Financial Officer at Absci Corp.
“On August 11, 2023, Gregory Schiffman, the Company’s Chief Financial Officer, notified the Company of his decision to retire.”
Absci Corp: Amendment to Amended and Restated Certificate of Incorporation to limit liability of certain officers (effective 2023-06-14).
“At the 2023 Annual Meeting of Stockholders of the Company held on June 14, 2023 (the “Annual Meeting”), the Company’s stockholders approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.”
Absci Corp shareholders approved Amendment to Amended and Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law at the 2023-04-17 meeting.
“The Company’s stockholders approved Proposal III. The votes cast at the Annual Meeting were as follows: For Against Abstain Broker Non-Votes 69,802,928 1,242,214 401,227 7,685,480”
Absci Corp shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-04-17 meeting.
“The Company’s stockholders approved Proposal II. The votes cast at the Annual Meeting were as follows: For Against Abstain 78,698,147 173,747 259,955”
Absci Corp shareholders approved Election of Daniel Rabinovitsj as Class II director at the 2023-04-17 meeting.
“The Company’s stockholders approved the Class II director nominee recommended for election in Proposal I at the Annual Meeting. The Company’s stockholders voted for the Class II director as follows: Class II Director Nominee For Withhold Broker Non-Votes Daniel Rabinovitsj 70,779,631 666,738 7,685,480”
Absci Corp entered into Agreement with Cowen and Company, LLC valued at up to $100 million (effective 2023-06-16).
“On June 16, 2023, Absci Corporation (the “Company”) entered into a sales agreement (the “Agreement”) with Cowen and Company, LLC, as sales agent (the “Sales Agent”), with respect to an “at the market offering” program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $100 million (the “Shares”) through the Sales Agent (the “Offering”).”
Frans van Houten was appointed as Director at Absci Corp.
“On June 2, 2023, the Board of Directors (the “Board”) of Absci Corporation (the “Company”) appointed Frans van Houten to the Board effective that same date.”
Absci Corp reported first quarter ended March 31, 2023 results: revenue $1.3 million, net income Net loss was $23.4 million.
“First Quarter 2023 Financial Results Revenue was $1.3 million for the three months ended March 31, 2023 compared to $0.8 million for the three months ended March 31, 2022. This increase was driven by partnered program mix and progress timing. Revenue in the first quarter of 2023 was impacted by timing of progress on the Merck research collaboration based on administrative delays, and Absci expects to recognize revenues from this collaboration throughout 2023. Research and development expenses were $12.7 million for the first quarter of 2023 compared to $15.8 million for the corresponding prior year period. This decrease was primarily driven by lower laboratory operational costs. Selling, general, and administrative expenses were $9.6 million for the first quarter of 2023 compared to $10.9 million for the corresponding prior year period. This decrease was primarily due to a reduction in insurance costs. Net loss was $23.4 million for the first quarter of 2023, as compared to $29.5 milli”
Absci Corp reported Full Year ended December 31, 2022 results: net income Net loss was $104.9 million for the year ended December 31, 2022 compared to $101.0 million for the year ended December.
“Revenue was $5.7 million for the year ended December 31, 2022 compared to $4.8 million for the year ended December 31, 2021.”
Absci Corp reported Fourth Quarter ended December 31, 2022 results: net income Net loss was $19.5 million for the fourth quarter of 2022, as compared to $25.2 million for the corresponding prior year.
“Revenue was $1.6 million for the three months ended December 31, 2022 compared to $1.5 million for the three months ended December 31, 2021.”
Absci Corp: The company's board of directors approved and adopted amended and restated bylaws to conform to recent DGCL amendments and universal proxy rules, among other changes (effective 2022-12-15).
“On December 15, 2022, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the “DGCL”), and a periodic review of the bylaws of Absci Corporation (the “Company”), the Company’s board of directors (the “Board”) approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.”
Absci Corp reported the quarter ended September 30, 2022 results: revenue $2.4 million. Guidance reaffirmed.
“Total Revenue was $2.4 million for the third quarter of 2022, as compared to $1.5 million for the third quarter of 2021.”
Dan Rabinovitsj was appointed as Director at Absci Corp.
“On November 1, 2022, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dan Rabinovitsj to the Board effective that same date.”
Matthew Weinstock changed role as Chief Technology Officer at Absci Corp.
“Matthew Weinstock, Ph.D., the Company's Chief Technology Officer, will transition into a consultant role on October 4, 2022.”
Andreas Busch was appointed as Chief Innovation Officer at Absci Corp.
“effective immediately upon his appointment as the Company's Chief Innovation Officer”
Andreas Busch resigned as Director at Absci Corp.
“he would resign from the Company's Board of Directors”
Nikhil Goel resigned as Chief Strategy Officer at Absci Corp.
“On September 15, 2022, Absci Corporation (the “Company”) and Nikhil Goel, the Company’s Chief Strategy Officer, agreed that Mr. Goel’s employment with the Company would end effective as of September 20, 2022.”
Eli Casdin resigned as Board of Directors at Absci Corp.
“On July 8, 2022, Eli Casdin notified Absci Corporation (the “Company”) that he would resign from the Company’s Board of Directors and all committees thereof, effective as of July 11, 2022.”
Andreas Busch was appointed as Director at Absci Corp.
“On March 17, 2022, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Andreas Busch to the Board effective that same date.”
Dr. Joseph Sirosh was appointed as Class III Director at Absci Corp.
“On January 7, 2022, the Board of Directors (the “Board”) of Absci Corporation (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Dr. Joseph Sirosh to the Board effective that same date.”
Andreas Pihl departed as Chief Operating Officer at Absci Corp.
“Andreas Pihl, the Company’s Chief Operating Officer, agreed that Mr. Pihl would retire from his employment with the Company after a transition period of up to approximately nine months, or by May 13, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.